{"prompt": "['Trelagliptin-4002', 'Page 3 of 66', 'Version 2.0', 'July 5,10', '1.0', 'STUDY ADMINISTRATIVE INFORMATION AND CLINICAL STUDY', 'PRINCIPLES', '1.1', 'Clinical study principles', 'This study will be conducted with the highest respect for the individual participants in accordance', 'with the requirements of this clinical study protocol and also in accordance with the following:', 'The ethical principles that have their origin in the Declaration of Helsinki.', 'Ethical Guideline for Clinical Research (the Ministry of Education, Culture, Sports, Science and', 'Technology and the Ministry of Health, Labour and Welfare, December 22, 2014).', 'Good Clinical Practice: Consolidated Guideline (ICH: International Conference on', 'Harmonization of Technical Requirement for Registration on Pharmaceuticals for Human Use.', 'E6)', 'All applicable laws and regulations, including, without limitation, data privacy laws and conflict', 'of interest guidelines.', '1.2', 'Clinical study implementation system', 'This study will be conducted in accordance with the requirements of this clinical study protocol', 'designed and prepared by the sponsor and also in accordance with the following. Other study', 'administrative structures are shown in the separate documents.', 'Sponsor', 'Japan Medical Affairs, Japan Pharma Business Unit, Takeda Pharmaceutical Company Limited', 'The sponsor shall be responsible for matters related to planning/preparation,', 'implementation/operation, and results/reporting in this clinical study. Methods of supervision of the', 'contractor entrusted with the services related to this clinical study will be described in the procedure', 'to be prepared separately.', 'Expenses* required for the operation of this clinical study will be paid by the sponsor.', '*', ': Based on the \"Consignment Service Contract,\" expenses incurred for the services of Office of', 'Clinical Study, monitoring, registration/allocation center, and statistical processing shall be paid', 'to the contractor entrusted with services related to this clinical study. Expenses agreed by the', 'study site shall be paid to the site based on the \"Research Expense Standard.\"', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 4 of 66', 'Version 2.0', 'July 5, 2017', 'Chair of the Clinical Study Steering Committee:', 'PPD', 'Terms in this protocol are defined as follows:', 'Study site:', 'A corporation, governmental agency and sole proprietor conducting the study, excluding cases', 'where only a part of the services related to storage of samples/information, statistical processing', 'and other studies are entrusted.', 'Investigators:', 'Principal investigators and other parties involved in conduction of the study (including operations', 'at institutions involved in collection/distribution of samples/information). Those involved only in', 'providing existing samples/information outside the study sites and those engaged in part of the', 'entrusted operations related to the study are excluded.', 'Principal Investigator:', 'An investigator who is engaged in implementation of the study and integrates the operations', 'involved in this study at an affiliated study site.', 'Chief executive of the study site:', 'A representative of a corporation, head of a governmental agency, or a sole proprietor', 'Study subject:', 'A subject (including a dead subject) who meets any of the following:', '1.', 'Subjects being studied (including those who have been asked to be studied)', '2.', 'Subjects from whom existing samples/information to be used in the study have been', 'obtained.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 5 of 66', 'Version 2.0', 'July 5, 2017', 'Table of Contents', '1.0', 'STUDY ADMINISTRATIVE INFORMATION AND CLINICAL STUDY', 'PRINCIPLES', '3', '1.1', 'Clinical study principles', '3', '1.2', 'Clinical study implementation system', '3', '2.0', 'STUDY SUMMARY', '10', '3.0', 'ABBREVIATION', '17', '4.0', 'INTRODUCTION', '18', '4.1', 'Background', '18', '4.2', 'Rationale for the proposed study', '18', '5.0', 'STUDY OBJECTIVES AND ENDPOINTS', '20', '5.1', 'Objectives', '20', '5.2', 'Definition of endpoints', '20', '5.2.1', 'Primary endpoints', '20', '5.2.2', 'Secondary endpoints', '20', '5.2.3', 'Other Endpoints', '21', '6.0', 'CLINICAL STUDY DESIGN', '22', '6.1', 'Clinical study design', '22', '6.2', 'Rationale for the clinical study design', '24', '6.3', 'Premature termination of entire clinical study or premature termination', 'of clinical study at a study site', '24', '6.3.1 Premature termination criteria of entire clinical study', '24', '6.3.2', 'Criteria for premature termination of study sites', '25', '6.3.3', 'Procedures of clinical study suspension and premature termination of', 'entire clinical study or clinical study at a study site', '25', '6.4', 'Procedures for protocol revision', '25', '7.0', 'SELECTION AND WITHDRAWAL CRITERIA OF STUDY SUBJECTS', '26', '7.1', 'Inclusion criteria', '26', '7.2', 'Exclusion criteria', '26', '7.3', 'Prohibited concomitant drugs and permitted concomitant drugs', '28', '7.4', 'Study subject management', '28', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}